A new mechanism of allostery in a G protein-coupled receptor dimer

Nature Chemical Biology

Volumn 10, Issue 9, 2014, Pages 745-752

  Lane, J Robert ^a   Donthamsetti, Prashant ^b,c   Shonberg, Jeremy ^a   Draper Joyce, Christopher J ^a   Dentry, Samuel ^a   Michino, Mayako ^d   Shi, Lei ^d   López, Laura ^a   Scammells, Peter J ^a   Capuano, Ben ^a   Sexton, Patrick M ^a   Javitch, Jonathan A ^b,c   Christopoulos, Arthur ^a  

^a MONASH UNIVERSITY   (Australia)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIMER; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; G PROTEIN COUPLED RECEPTOR; HYBRID PROTEIN; LIGAND;

ALLOSTERISM; ARTICLE; DRUG BINDING; LIGAND BINDING; MOLECULAR DOCKING; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN DOMAIN; RAT; TISSUES;

ALLOSTERIC REGULATION; ANIMALS; BINDING SITES; DOPAMINE AGENTS; HUMANS; LIGANDS; MODELS, MOLECULAR; NEOSTRIATUM; PROTEIN CONFORMATION; PROTEIN TRANSPORT; RATS; RECEPTORS, DOPAMINE D2; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 84906306554     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.1593     Document Type: Article

References (59)

1. Jacoby, E., Bouhelal, R., Gerspacher, M. & Seuwen, K. The 7 TM G-protein-coupled receptor target family. ChemMedChem 1, 761-782 (2006).
2. Lagerström, M.C. & Schiöth, H.B. Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat. Rev. Drug Discov. 7, 339-357 (2008).
3. Kenakin, T. & Miller, L.J. Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol. Rev. 62, 265-304 (2010).
4. Mohr, K. et al. Rational design of dualsteric GPCR ligands: quests and promise. Br. J. Pharmacol. 159, 997-1008 (2010).
5. Lane, J.R., Sexton, P.M. & Christopoulos, A. Bridging the gap: bitopic ligands of G-protein-coupled receptors. Trends Pharmacol. Sci. 34, 59-66 (2013).
6. Valant, C. et al. A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand. J. Biol. Chem. 283, 29312-29321 (2008).
7. Antony, J. et al. Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity. FASEB J. 23, 442-450 (2009).
8. Keov, P. et al. Reverse engineering of the selective agonist TBPB unveils both orthosteric and allosteric modes of action at the M1 muscarinic acetylcholine receptor. Mol. Pharmacol. 84, 425-437 (2013).
9. Beaulieu, J.-M. & Gainetdinov, R.R. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol. Rev. 63, 182-217 (2011).
10. Löber, S., Hübner, H., Tschammer, N. & Gmeiner, P. Recent advances in the search for D3- and D4-selective drugs: probes, models and candidates. Trends Pharmacol. Sci. 32, 148-157 (2011).
11. Reavill, C. et al. Pharmacological actions of a novel, high-affinity, and selective human dopamine D3 receptor antagonist, SB-277011-A. J. Pharmacol. Exp. Ther. 294, 1154-1165 (2000).
12. Stemp, G. et al. Design and synthesis of trans-N-[4-[2-(6-cyano-1,2,3,4- tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarboxamide (SB-277011): a potent and selective dopamine D3 receptor antagonist with high oral bioavailability and CNS penetration in the rat. J. Med. Chem. 43, 1878-1885 (2000).
13. Zhang, A., Neumeyer, J.L. & Baldessarini, R.J. Recent progress in development of dopamine receptor subtype-selective agents: potential therapeutics for neurological and psychiatric disorders. Chem. Rev. 107, 274-302 (2007).
14. Silvano, E. et al. The tetrahydroisoquinoline derivative SB269,652 is an allosteric antagonist at dopamine D3 and D2 receptors. Mol. Pharmacol. 78, 925-934 (2010).
15. Han, Y., Moreira, I.S., Urizar, E., Weinstein, H. & Javitch, J.A. Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation. Nat. Chem. Biol. 5, 688-695 (2009).
16. Armstrong, D. & Strange, P.G. Dopamine D2 receptor dimer formation: evidence from ligand binding. J. Biol. Chem. 276, 22621-22629 (2001).
17. Vivo, M., Lin, H. & Strange, P.G. Investigation of cooperativity in the binding of ligands to the D2 dopamine receptor. Mol. Pharmacol. 69, 226-235 (2006).
18. Christopoulos, A. & Kenakin, T. G protein-coupled receptor allosterism and complexing. Pharmacol. Rev. 54, 323-374 (2002).
19. Leach, K., Sexton, P.M. & Christopoulos, A. Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. Trends Pharmacol. Sci. 28, 382-389 (2007).
20. Christopoulos, A. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat. Rev. Drug Discov. 1, 198-210 (2002).
21. Chien, E.Y.T. et al. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science 330, 1091-1095 (2010).
22. Newman, A.H. et al. Molecular determinants of selectivity and efficacy at the dopamine D3 receptor. J. Med. Chem. 55, 6689-6699 (2012).
23. Michino, M. et al. A single glycine in extracellular loop 1 is the critical determinant for pharmacological specificity of dopamine D2 and D3 receptors. Mol. Pharmacol. 84, 854-864 (2013).
24. Ferré, S. et al. Building a new conceptual framework for receptor heteromers. Nat. Chem. Biol. 5, 131-134 (2009).
25. Guo, W. et al. Dopamine D2 receptors form higher order oligomers at physiological expression levels. EMBO J. 27, 2293-2304 (2008).
26. Vilardaga, J.-P. et al. Conformational cross-talk between α2A-adrenergic and μ-opioid receptors controls cell signaling. Nat. Chem. Biol. 4, 126-131 (2008).
27. Dorsch, S., Klotz, K.-N., Engelhardt, S., Lohse, M.J. & Bünemann, M. Analysis of receptor oligomerization by FRAP microscopy. Nat. Methods 6, 225-230 (2009).
28. Kasai, R.S. et al. Full characterization of GPCR monomer-dimer dynamic equilibrium by single molecule imaging. J. Cell Biol. 192, 463-480 (2011).
29. Hern, J.A. et al. Formation and dissociation of M1 muscarinic receptor dimers seen by total internal reflection fluorescence imaging of single molecules. Proc. Natl. Acad. Sci. USA 107, 2693-2698 (2010).
30. Fonseca, J.M. & Lambert, N.A. Instability of a class A G protein-coupled receptor oligomer interface. Mol. Pharmacol. 75, 1296-1299 (2009).
31. Damian, M., Martin, A., Mesnier, D., Pin, J.-P. & Banères, J.-L. Asymmetric conformational changes in a GPCR dimer controlled by G-proteins. EMBO J. 25, 5693-5702 (2006).
32. Albizu, L. et al. Probing the existence of G protein-coupled receptor dimers by positive and negative ligand-dependent cooperative binding. Mol. Pharmacol. 70, 1783-1791 (2006).
33. Springael, J.-Y. et al. Allosteric modulation of binding properties between units of chemokine receptor homo- and hetero-oligomers. Mol. Pharmacol. 69, 1652-1661 (2006).
34. May, L.T., Bridge, L.J., Stoddart, L.A., Briddon, S.J. & Hill, S.J. Allosteric interactions across native adenosine-A3 receptor homodimers: quantification using single-cell ligand-binding kinetics. FASEB J. 25, 3465-3476 (2011).
35. Seeman, P. Targeting the dopamine D2 receptor in schizophrenia. Expert Opin. Ther. Targets 10, 515-531 (2006).
36. Gregory, K.J., Sexton, P.M. & Christopoulos, A. Allosteric modulation of muscarinic acetylcholine receptors. Curr. Neuropharmacol. 5, 157-167 (2007).
37. Kruse, A.C. et al. Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature 504, 101-106 (2013).
38. Bock, A. et al. The allosteric vestibule of a seven transmembrane helical receptor controls G-protein coupling. Nat. Commun. 3, 1044 (2012).
39. Kuszak, A.J. et al. Purification and functional reconstitution of monomeric μ-opioid receptors: allosteric modulation of agonist binding by Gi2. J. Biol. Chem. 284, 26732-26741 (2009).
40. Whorton, M.R. et al. A monomeric G protein-coupled receptor isolated in a high-density lipoprotein particle efficiently activates its G protein. Proc. Natl. Acad. Sci. USA 104, 7682-7687 (2007).
41. Bayburt, T.H., Leitz, A.J., Xie, G., Oprian, D.D. & Sligar, S.G. Transducin activation by nanoscale lipid bilayers containing one and two rhodopsins. J. Biol. Chem. 282, 14875-14881 (2007).
42. Milligan, G. G protein-coupled receptor hetero-dimerization: contribution to pharmacology and function. Br. J. Pharmacol. 158, 5-14 (2009).
43. Albizu, L. et al. Time-resolved FRET between GPCR ligands reveals oligomers in native tissues. Nat. Chem. Biol. 6, 587-594 (2010).
44. Park, P.S.H., Sum, C.S., Pawagi, A.B. & Wells, J.W. Cooperativity and oligomeric status of cardiac muscarinic cholinergic receptors. Biochemistry 41, 5588-5604 (2002).
45. Smith, N.J. & Milligan, G. Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes. Pharmacol. Rev. 62, 701-725 (2010).
46. Canals, M. et al. Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J. Biol. Chem. 278, 46741-46749 (2003).
47. Rashid, A.J. et al. D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum. Proc. Natl. Acad. Sci. USA 104, 654-659 (2007).
48. Navarro, G. et al. Interactions between calmodulin, adenosine A2A, and dopamine D2 receptors. J. Biol. Chem. 284, 28058-28068 (2009).
49. Carriba, P. et al. Detection of heteromerization of more than two proteins by sequential BRET-FRET. Nat. Methods 5, 727-733 (2008).
50. Shonberg, J. et al. A structure-activity analysis of biased agonism at the dopamine D2 receptor. J. Med. Chem. 56, 9199-9221 (2013).
51. Canals, M. et al. A Monod-Wyman-Changeux mechanism can explain G protein-coupled receptor (GPCR) allosteric modulation. J. Biol. Chem. 287, 650-659 (2012).
52. Yeatman, H.R. et al. Allosteric modulation of M1 muscarinic acetylcholine receptor internalization and subcellular trafficking. J. Biol. Chem. 289, 15856-15866 (2014).
53. Sherman, W., Day, T., Jacobson, M.P., Friesner, R.A. & Farid, R. Novel procedure for modeling ligand/receptor induced fit effects. J. Med. Chem. 49, 534-553 (2006).
54. Cho, A.E., Guallar, V., Berne, B.J. & Friesner, R. Importance of accurate charges in molecular docking: quantum mechanical/molecular mechanical (QM/MM) approach. J. Comput. Chem. 26, 915-931 (2005).
55. Bowers, K.J. et al. in Proceedings of the 2006 ACM/IEEE Conference on Supercomputing 43 (ACM, New York, 2006).
56. Motulsky, H.J. & Christopoulos, A. Fitting Models to Biological Data Using Linear and Nonlinear Regression: a Practical guide to Curve Fitting (GraphPad Software Inc., San Diego CA., 2003).
57. Leach, K. et al. Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties. Neuropsychopharmacology 35, 855-869 (2010).
58. Nawaratne, V., Leach, K., Felder, C.C., Sexton, P.M. & Christopoulos, A. Structural determinants of allosteric agonism and modulation at the M4 muscarinic acetylcholine receptor: identification of ligand-specific and global activation mechanisms. J. Biol. Chem. 285, 19012-19021 (2010).
59. May, L.T., Leach, K., Sexton, P.M. & Christopoulos, A. Allosteric modulation of G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 47, 1-51 (2007).